PALO ALTO, Calif., Jan. 7 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2008 at 7:30 a.m. Pacific time (10:30 a.m. Eastern time). A live and archived webcast of the presentation will be available on the Telik website, http://www.telik.com.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(TM), which is in clinical development for the treatment of myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates.
|SOURCE Telik, Inc.|
Copyright©2008 PR Newswire.
All rights reserved